Although, the expression of PD-1 was higher in AML patients (12.98 ± 17.64) compared with healthy donors (4.85 ± 6.58), the differences were not statistically significant, showing a high variability in the expression of this checkpoint in AML patients (Fig. 2c). This evidence concerns the gene PDCD1 and acute myeloid leukemia.